TY - JOUR
T1 - The immune checkpoint PD-1 in natural killer cells
T2 - Expression, function and targeting in tumour immunotherapy
AU - Quatrini, Linda
AU - Mariotti, Francesca Romana
AU - Munari, Enrico
AU - Tumino, Nicola
AU - Vacca, Paola
AU - Moretta, Lorenzo
N1 - Funding Information:
This work was supported by grants awarded by Associazione Italiana per la Ricerca sul Cancro (AIRC)-Special Program Metastatic disease: the key unmet need in oncology 5X1000 2018 Id. 21147 (L.M.), AIRC IG 2017 Id. 19920 (L.M.); RC-2020 OPBG (L.M., P.V.); L.Q. has received funding from AIRC and from the European Union's Horizon 2020 research and innovation programme under the Marie Sk?odowska-Curie grant agreement no 800924; F.R.M. is recipient of Fondazione Umberto Veronesi fellowship; N.T. is supported by a AIRC fellowship for Italy. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results,.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/11
Y1 - 2020/11
N2 - In the last years, immunotherapy with antibodies against programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has shown remarkable efficacy in the treatment of different types of tumours, representing a true revolution in oncology. While its efficacy has initially been attributed only to unleashing T cell responses, responsivity to PD-1/PD-L1 blockade was observed in some tumours with low Human Leukocyte Antigen (HLA) I expression and increasing evidence has revealed PD-1 surface expression and inhibitory function also in natural killer (NK) cells. Thus, the contribution of anti-PD-1/PD-L1 therapy to the recovery of NK cell anti-tumour response has recently been appreciated. Here, we summarize the studies investigating PD-1 expression and function in NK cells, together with the limitations and perspectives of immunotherapies. A better understanding of checkpoint biology is needed to design next-generation therapeutic strategies and to improve the clinical protocols of current therapies.
AB - In the last years, immunotherapy with antibodies against programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has shown remarkable efficacy in the treatment of different types of tumours, representing a true revolution in oncology. While its efficacy has initially been attributed only to unleashing T cell responses, responsivity to PD-1/PD-L1 blockade was observed in some tumours with low Human Leukocyte Antigen (HLA) I expression and increasing evidence has revealed PD-1 surface expression and inhibitory function also in natural killer (NK) cells. Thus, the contribution of anti-PD-1/PD-L1 therapy to the recovery of NK cell anti-tumour response has recently been appreciated. Here, we summarize the studies investigating PD-1 expression and function in NK cells, together with the limitations and perspectives of immunotherapies. A better understanding of checkpoint biology is needed to design next-generation therapeutic strategies and to improve the clinical protocols of current therapies.
KW - Glucocorticoids
KW - Immunotherapy
KW - Inhibitory checkpoints
KW - NK cells
KW - PD-1
KW - PD-L1
KW - Soluble PD-1
KW - Tumour microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85095707107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095707107&partnerID=8YFLogxK
U2 - 10.3390/cancers12113285
DO - 10.3390/cancers12113285
M3 - Review article
AN - SCOPUS:85095707107
VL - 12
SP - 1
EP - 21
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 11
M1 - 3285
ER -